TADPOL: DFMO/polyamine pathway in recent-onset T1D
What this study tests
Randomized phase 2 study testing difluoromethylornithine (DFMO), a polyamine-pathway drug, to reduce beta-cell stress and preserve remaining insulin production in recent-onset T1D.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-08-21.
Most recent recorded citation date: 2026-08-21. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- People aged 4-40 diagnosed with type 1 diabetes within the past 100 days (insulin started no more than 100 days before randomisation), with residual insulin production (random non-fasting C-peptide above 0.2 pmol/mL, i.e. above 0.6 ng/mL) and at least one T1D autoantibody. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. Enrolment is closed (active, not recruiting). The live registry (last update 21 August 2026) lists actual enrolment 74, not the earlier estimated 81, and estimated primary/study completion June 2027.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Clinical efficacy of oral DFMO after 6 months
- Treatment-related adverse events
The full picture
What it is and why it matters. TADPOL is testing whether an older repurposed drug can help newly diagnosed people hold on to the insulin-making cells they still have. Most people diagnosed with type 1 diabetes still have some working beta cells for months or years afterwards, and keeping even a little of that insulin production makes blood sugar easier to control. The drug, DFMO (difluoromethylornithine), targets the polyamine pathway; the hypothesis stated in the registry is that it reduces stress on insulin-making cells and preserves remaining insulin production, rather than suppressing the immune system itself.1
How it is designed. This is a randomised, placebo-controlled phase 2 trial in people aged 4-40 whose insulin was started no more than 100 days before randomisation, who still have measurable C-peptide (random non-fasting C-peptide above 0.2 pmol/mL, a marker of their own insulin production), and who carry at least one T1D autoantibody. Participants are randomised 2:1 to take oral DFMO at 1000 mg/m2/day or a placebo for 6 months. What makes the design interesting is what comes next: a 6-month washout with no drug, to test whether any preserved insulin production survives after treatment stops.1
Where it stands. Enrolment is closed and the trial is active but no longer recruiting, so it is now in follow-up. The live registry lists actual enrolment 74 (the earlier 81 figure was an estimate) and estimated primary completion June 2027. No results have been posted — so anyone reading about it today is reading about a hypothesis, not an outcome.1
Sources
- [1]NCT05594563: TADPOL: DFMO/polyamine pathway in recent-onset T1D · Trial registry · 2026-08-21 — Live registry 21–27 August 2026: ACTIVE_NOT_RECRUITING; actual n=74; estimated primary completion June 2027; no results posted.
ClinicalTrials.gov. TADPOL: TArgeting Type 1 Diabetes Using POLyamines (NCT05594563). U.S. National Library of Medicine.
ClinicalTrials.gov. NCT05594563 record — eligibility, dosing and washout design.
ClinicalTrials.gov. NCT05594563 record — ACTIVE_NOT_RECRUITING; actual n=74; estimated primary completion June 2027; no results posted (live-checked 27 August 2026).